RA Capital Management L.P. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

RA Capital Management L.P. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 5.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,381,144 shares of the company's stock after purchasing an additional 331,940 shares during the quarter. Dyne Therapeutics comprises 2.6% of RA Capital Management L.P.'s holdings, making the stock its 11th largest holding. RA Capital Management L.P. owned 6.27% of Dyne Therapeutics worth $229,211,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in DYN. AQR Capital Management LLC boosted its stake in Dyne Therapeutics by 4.3% during the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company's stock valued at $300,000 after purchasing an additional 352 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock worth $26,000 after buying an additional 669 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company's stock valued at $123,000 after buying an additional 709 shares during the last quarter. KBC Group NV lifted its stake in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after acquiring an additional 751 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company's stock worth $99,000 after acquiring an additional 796 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DYN shares. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Guggenheim raised their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, August 15th. Oppenheimer restated an "outperform" rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, Chardan Capital reissued a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $50.82.

Dyne Therapeutics Stock Down 4.9 %

Dyne Therapeutics stock traded down $1.45 during trading hours on Thursday, hitting $27.99. The stock had a trading volume of 250,050 shares, compared to its average volume of 1,461,662. The stock has a market capitalization of $2.85 billion, a P/E ratio of -8.03 and a beta of 1.09. The stock's 50-day moving average price is $31.34 and its 200-day moving average price is $35.44. Dyne Therapeutics, Inc. has a 12-month low of $10.33 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares of the company's stock, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,257 shares of company stock worth $6,193,718. Insiders own 20.77% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.